Interacciones de Vincristina

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. (etiqueta de Vincristina, Advertencia en recuadro)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (etiqueta de Citarabina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (etiqueta de Doxorubicina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

…drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh… (etiqueta de Ganciclovir, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

…associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine) Unknown Because of potential for higher toxicity, coadministration with valganciclovir hydrochloride should be considered only if the potential benefits… (etiqueta de Valganciclovir, Interacciones medicamentosas)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (etiqueta de Vasopresina, Interacciones medicamentosas)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

…baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12 . (etiqueta de Bortezomib, Advertencias y precauciones)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)

Concurrent use of strong CYP3A inducers (e.g., St. (etiqueta de Vincristina, Interacciones medicamentosas)